Screening policy for cystic fibrosis: the role of evidence.
D003256:Community Participation; D016265:Conflict of Interest; D003550:Cystic Fibrosis; D003657:Decision Making; D005069:Evaluation Studies as Topic; D005378:Financial Support; D005817:Genetic Counseling; D033142:Genetic Services; D005820:Genetic Testing; D006579:Heterozygote; D006801:Humans; D007221:Industry; D007231:Infant, Newborn; D008403:Mass Screening; D009316:National Institutes of Health (U.S.); D016134:Organizational Policy; D010344:Patient Advocacy; D011050:Policy Making; D011057:Politics; D011287:Prejudice; D011379:Prognosis; D011640:Public Policy; D012015:Reference Standards; D027724:Reproductive Techniques, Assisted; D012306:Risk; D018570:Risk Assessment; D012935:Social Justice; D012952:Societies; D016896:Treatment Outcome; D014481:United States
American Society of Human Genetics; Analytical Approach; Genetics and Reproduction; National Institutes of Health; Office of Technology Assessment